Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients

HDAC genes are thought to be involved in gene expression through the regulation of chromatin structure, alterations of which may cause abnormal gene silencing in cancers. To clarify the possible role of HDAC genes during tumor development and progression, we studied their expression and influence on clinical features. Expression levels of HDAC class I and class II genes in cancer tissues resected from 72 patients with NSCLC were measured with real‐time RT‐PCR. Their association with clinicopathologic features was statistically investigated. Reduced expression of each class II HDAC gene was significantly associated with poor prognosis and an independent predictor of poor prognosis. Of all the genes, HDAC10 was the strongest predictor of poor prognosis. Hierarchical clustering analysis showed that lung cancer tissues could be divided into 3 groups based on the expression level of class I and class II HDAC genes. The group with reduced expression of class II HDACs showed poor prognosis. These results suggest that class II HDACs may repress critical genes and that low expression of these genes may play a role in lung cancer progression. Results of clustering analyses imply that class II HDAC genes may be regulated by a similar mechanism and deregulated during cancer development. © 2004 Wiley‐Liss, Inc.

[1]  C. Carpenter,et al.  DNA methylation analysis: a powerful new tool for lung cancer diagnosis , 2002, Oncogene.

[2]  Ricardo Macarron,et al.  Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.

[3]  J. Minna,et al.  Molecular genetics of lung cancer. , 1988, Annual review of medicine.

[4]  P. Chambon,et al.  Selective interaction between the chromatin‐remodeling factor BRG1 and the heterochromatin‐associated protein HP1α , 2002, The EMBO journal.

[5]  M. Rosenfeld,et al.  Biological roles and mechanistic actions of co-repressor complexes. , 2002, Journal of cell science.

[6]  Chun Li Zhang,et al.  Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy , 2002, Cell.

[7]  H. Youn,et al.  Cabin1 represses MEF2-dependent Nur77 expression and T cell apoptosis by controlling association of histone deacetylases and acetylases with MEF2. , 2000, Immunity.

[8]  S. Khochbin,et al.  Class II Histone Deacetylases Are Directly Recruited by BCL6 Transcriptional Repressor* , 2002, The Journal of Biological Chemistry.

[9]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[10]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[11]  G. Fishman,et al.  Regulation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and mitochondrial function by MEF2 and HDAC5 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[13]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[14]  G. Zhu,et al.  Functional Characterization of an Amino-terminal Region of HDAC4 That Possesses MEF2 Binding and Transcriptional Repressive Activity* , 2003, Journal of Biological Chemistry.

[15]  Weidong Wang,et al.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. , 2003, Cancer research.

[16]  S. Schreiber,et al.  Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Hendrix,et al.  Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. , 2000, Cancer research.

[18]  E. Olson,et al.  Association of Class II Histone Deacetylases with Heterochromatin Protein 1: Potential Role for Histone Methylation in Control of Muscle Differentiation , 2002, Molecular and Cellular Biology.

[19]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[20]  J. Herman,et al.  DNA methylation, chromatin inheritance, and cancer , 2001, Oncogene.

[21]  K. Yanagisawa,et al.  Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines. , 2001, Cancer research.

[22]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[23]  H. Osada,et al.  Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer , 2002, Oncogene.

[24]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[25]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.